D24-RGD-loaded MSCs

D24-RGD-loaded MSCs (MSC-D24) is an investigational cell-mediated oncolytic virus therapy being developed for the treatment of high-grade gliomas, including diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG). The therapy utilizes mesenchymal stem cells (MSCs) as delivery vehicles to transport D24-RGD (tasadenoturev), a replication-competent oncolytic adenovirus, directly to the tumor site. D24-RGD is genetically engineered with a 24-base pair deletion in the E1A gene to restrict its replication to cells with a dysfunctional retinoblastoma (Rb) pathway, and an RGD-4C peptide motif in the fiber knob to enhance viral entry via alpha-v integrins. By packaging the virus within MSCs, the therapy aims to protect the viral payload from host immune neutralization and leverage the natural tumor-homing capabilities of MSCs. Clinical delivery is typically achieved through super-selective intra-arterial infusion to maximize local drug concentration in the brain and bypass the blood-brain barrier.

Other names

MSC-DNX-2401MSC-DNX2401MSC-DNX 2401D24-RGD-loaded mesenchymal stem cellsD-24-RGD-loaded mesenchymal stem cellsD 24-RGD-loaded mesenchymal stem cells